Literature DB >> 10520648

Influenza.

N J Cox1, K Subbarao.   

Abstract

Influenza is the most frequent cause of acute respiratory illness requiring medical intervention because it affects all age groups and because it can recur in any individual. During the past three decades, efforts to prevent and control influenza have focused primarily on the use of inactivated influenza vaccines in elderly people and in individuals with chronic medical conditions that put them at risk for complications. However, the continuing impact of influenza in these and other population groups has motivated the development of novel approaches for prevention and control of influenza. Several important advances in the field of influenza have occurred in the last few years. An experimental live, attenuated, intranasally administered trivalent influenza vaccine was shown to be highly effective in protecting young children against influenza A H3N2 and influenza B. New antiviral drugs based on the structure of the neuraminidase molecule were assessed in clinical trials and found to be effective against influenza A and B viruses. The expected use of these new antiviral agents has accelerated the development of rapid point-of-care diagnostic tests. The availability of new diagnostic tests, new antiviral drugs, and new vaccines will undoubtedly alter our approaches to influenza control and have an impact on clinical practice.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10520648     DOI: 10.1016/S0140-6736(99)01241-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  225 in total

1.  How to treat influenza and colds.

Authors:  M C Kim; N P Lee
Journal:  West J Med       Date:  2000-04

2.  Mass influenza vaccination in Ontario: a sensible move.

Authors:  R E Schabas
Journal:  CMAJ       Date:  2001-01-09       Impact factor: 8.262

3.  Infections Associated with Health-care Personnel: Vaccine-preventable Diseases and Bloodborne Pathogens.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-12       Impact factor: 3.725

4.  Depletion of human NK and CD8 cells prior to in vitro H1N1 flu vaccine stimulation increases the number of gamma interferon-secreting cells compared to the initial undepleted population in an ELISPOT assay.

Authors:  Christophe Dercamp; Violette Sanchez; Julie Barrier; Emanuelle Trannoy; Bruno Guy
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

5.  An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice.

Authors:  Yuk-Fai Lau; Lay-Hoon Tang; Amber W McCall; Eng-Eong Ooi; Kanta Subbarao
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

Review 6.  Oseltamivir: a review of its use in influenza.

Authors:  K McClellan; C M Perry
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Receptor tyrosine kinase inhibitors that block replication of influenza a and other viruses.

Authors:  Naveen Kumar; Nishi R Sharma; Hinh Ly; Tristram G Parslow; Yuying Liang
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

8.  Clinical and epidemiological characteristics of patients with influenza A (H1N1) 2009 attended to at the emergency room of a children's hospital.

Authors:  Esther Lera; Núria T Wörner; Mónica Sancosmed; Anna Fàbregas; Alejandro Casquero; Susana Melendo; Mar Miserachs; Teresa Tórtola; Astrid Borrego; Magda Campins; Fernando Moraga; Concepció Figueras; Rocío Cebrián
Journal:  Eur J Pediatr       Date:  2011-01-28       Impact factor: 3.183

Review 9.  Pandemic influenza planning in nursing homes: are we prepared?

Authors:  Lona Mody; Sandro Cinti
Journal:  J Am Geriatr Soc       Date:  2007-09       Impact factor: 5.562

Review 10.  Immunobiology of influenza vaccines.

Authors:  Margarita M Gomez Lorenzo; Matthew J Fenton
Journal:  Chest       Date:  2013-02-01       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.